Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 239

Results For "IMI"

4144 News Found

Aptar Digital Health and Healint collaborate for Central Nervous System
Digitisation | May 01, 2023

Aptar Digital Health and Healint collaborate for Central Nervous System

The partnership will capitalize on the combined capabilities of the two organizations


Aarti Drugs reports Q4 FY23 PAT at Rs.56.02 Cr
News | April 30, 2023

Aarti Drugs reports Q4 FY23 PAT at Rs.56.02 Cr

Specialty Chemicals grew 38% YoY for FY23


Biocon Biologics' new mAbs facility receives EU GMP Certification for bBevacizumab
News | April 29, 2023

Biocon Biologics' new mAbs facility receives EU GMP Certification for bBevacizumab

This approval reflects Biocon Biologics' compliance with the highest international regulatory standards


TPAG organizes Thalassemia & SCD prevention discussion
News | April 29, 2023

TPAG organizes Thalassemia & SCD prevention discussion

The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally


Yuyu Pharma unveils the results of its studies for its dry eye treatment peptide
News | April 28, 2023

Yuyu Pharma unveils the results of its studies for its dry eye treatment peptide

The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science


Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData
News | April 28, 2023

Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData

The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework


Ipca Laboratories gets 3 observations for Piparia, Silvassa unit
Drug Approval | April 27, 2023

Ipca Laboratories gets 3 observations for Piparia, Silvassa unit

The company will submit its comprehensive response on these observations to the US FDA within the stipulated time


Biocon approves NCD issue
News | April 27, 2023

Biocon approves NCD issue

The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.


Syngene International posts Q4 FY2023 consolidated profit at Rs. 178.7 Cr
News | April 27, 2023

Syngene International posts Q4 FY2023 consolidated profit at Rs. 178.7 Cr

The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023